Method of screening placental proteins responsible for pathophysiology of preeclampsia, and marker for early diagnosis and prediction of preeclampsia

Abstract

The present invention relates to a method of screening placental proteins responsible for pathophysiology of preeclampsia, and a marker for early diagnosis and prediction of preeclampsia. In accordance with one aspect of the present invention, there is provided a method of screening placental proteins responsible for pathophysiology of preeclampsia by 2D E-proteomics analysis, comprising: isolating placental proteins from a placental tissue; separating the isolated proteins two-dimensionally through 2D electrophoresis; and comparing and analyzing the separated proteins based on scanned gel images and differences in the images between normal placental proteins and preeclamptic placental proteins, wherein the comparison and analysis of the placental proteins based on the scanned gel images and differences in the images are accomplished by selecting proteins with differences of 140% or more between two placentas.

1 - 6 . (canceled) 
     
     
         7 . A method of using a marker for early diagnosis and prediction of preeclampsia, comprising:
 selecting one or more proteins from the protein group consisting of ER-60 protease, aldehyde reductase 1, fidaresta chain B bonded to human aldose reductase, voltage-dependent anion channel 1, nuclear chloride channel, cathepsin D chain H, phosphoglycerate mutase 1, endoplasmic reticulum protein, proteasome subunit alpha type-2 (PSMA2) protein, glutathione S-transferase, Ig heavy chain v region, and smooth muscle myosin alkali light chain, wherein the one or more proteins are isolated from a placental tissue and the isolated proteins are separated two-dimensionally through 2D electrophoresis; and   analyzing the isolated and separated proteins based on scanned gel images and differences in the images against normal placental proteins, wherein the marker for early diagnosis and prediction of preeclampsia shows an increased expression of 140% or more than the normal placental proteins based on scanned gel images and differences in the images against the normal placental proteins.   
     
     
         8 . The method of  claim 7 , wherein the ER-60 protease, aldehyde reductase 1, fidaresta chain B bonded to human aldose reductase, voltage-dependent anion channel 1, nuclear chloride channel, cathepsin D chain H, phosphoglycerate mutase 1, endoplasmic reticulum protein, PSMA2 protein, glutathione S-transferase, Ig heavy chain v region, and smooth muscle myosin alkali light chain have the sequences of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, respectively.